Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Zalfermin in Overweight or Obesity
NCT03479892Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2018
- Primary completion
- Jun 2019
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing NNC0194-0499 with Placebo (2 arms). Primary endpoint: Number of treatment emergent adverse events. Started Mar 2018; status: completed.
02
Drugs
nn9500
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03479892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03479892.